Clinical Trial Update: Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether nebivolol can protect against trastuzumab-induced cardiotoxicity in patients with HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nebivolol (Nebivolol)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Ain Shams University | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING